drugset / Trial / NCT04171687

Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers

NCT04171687

Phase 1 Completed 36 enrolled HK inno.N Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to evaluate the influence of tegoprazan or RAPA113 on the pharmacodynamics/Pharmacokinetics of following co-administration of tegoprazan or RAPA113 and clopidogrel in healthy male volunteers.

Timeline

Start
2019-10-21
Primary completion
2020-02-07
Completion
2020-04-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject RAPA113 Unknown Oral
Subject Tegoprazan Other / unclassified 50 mg Oral

Indications

No indication recorded.